Cognition Therapeutics Inc (CGTX) · Nov 5, 2026 · Earnings
Beat — EPS $(0.04) vs ~$0.07 loss consensus
Cognition Therapeutics’ earnings beat the published loss estimate, but a new Nasdaq bid-price deficiency adds a separate financing and listing risk.
Cognition is a grant-supported, clinical-stage biotech advancing zervimesine toward a planned registrational DLB study while waiting for Phase 2 START Alzheimer’s results in the second half of 2027. Its prior quarter had already pointed to FDA alignment and a mid-2027 development path, so the clinical update is mainly execution detail rather than a wholly new strategic direction.
The quarter itself beat the limited published EPS benchmark. Cognition reported a $0.04 per-share loss versus an external consensus estimate of roughly $0.07, while the absolute loss narrowed from $4.9 million to $4.1 million year over year. The beat is real, but this is a pre-revenue biotech, so the operating result is less important than clinical progress and financing capacity.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss (Financial Highlights) | $4.1M | $4.9M | |
| Diluted EPS (Financial Highlights) | $(0.04) | $(0.06) | $(0.07) |
| R&D expense (Financial Highlights) | $5.1M | $3.8M | |
| Cash and restricted cash (Balance Sheet) | $31.5M | $37.0M* | |
| Cash runway (Business Update) | Q4 2027 |
*December 31, 2025.
The pipeline is advancing, but the key clinical proof point remains distant. The company says FDA work produced a protocol for a planned registrational DLB study, with manufacturing, site selection and recruitment still under evaluation. START remains the larger Alzheimer’s catalyst, but topline data are not expected until the second half of 2027. 〔0〕 〔1〕
Funding looks adequate on the company’s stated plan, but the new Nasdaq deficiency is the filing’s most consequential surprise. Cash was $31.5 million, with $18.2 million of obligated grant funds remaining, and management estimates funding into the fourth quarter of 2027. However, the company disclosed that its bid price had stayed below $1.00 for 30 consecutive business days, giving it until May 3, 2027 to regain compliance. A second 180-day period may be available, but a reverse split could become necessary and delisting remains a stated risk.
Bottom line: The operating quarter modestly beat expectations and the drug program is moving forward, but those positives were largely incremental. The new Nasdaq compliance clock adds a material capital-markets and listing complication, making the overall filing mixed and slightly negative despite the EPS beat.
START topline results, second half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!